Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Johnson and Johnson
Moodys
McKesson
Harvard Business School

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR COUMADIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Coumadin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000469 ↗ Asymptomatic Carotid Artery Plaque Study (ACAPS) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 1988-05-01 To determine whether warfarin or lovastatin alone or in combination retarded the progression of atherosclerotic plaques in the carotid arteries of high risk individuals with asymptomatic carotid stenosis. Also, to determine if a full scale trial was feasible.
NCT00003915 ↗ Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment Completed Dana-Farber Cancer Institute Phase 2 2004-03-01 The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer. This study will attempt to: - stop or slow the growth of disease - gain information about prostate cancer - evaluate the effectiveness and side effects of the study drug
NCT00003915 ↗ Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment Completed University of Massachusetts, Worcester Phase 2 2004-03-01 The purpose of this study is to see if the combination of chemotherapy drugs and drugs to suppress testosterone (hormone therapy) is effective in controlling early prostate cancer. This study will attempt to: - stop or slow the growth of disease - gain information about prostate cancer - evaluate the effectiveness and side effects of the study drug
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Coumadin

Condition Name

Condition Name for Coumadin
Intervention Trials
Atrial Fibrillation 23
Healthy 7
Prostate Cancer 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Coumadin
Intervention Trials
Atrial Fibrillation 30
Thrombosis 24
Venous Thrombosis 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Coumadin

Trials by Country

Trials by Country for Coumadin
Location Trials
United States 518
Canada 54
United Kingdom 35
China 31
Japan 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Coumadin
Location Trials
Texas 33
California 24
Florida 21
New York 20
Massachusetts 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Coumadin

Clinical Trial Phase

Clinical Trial Phase for Coumadin
Clinical Trial Phase Trials
Phase 4 31
Phase 3 23
Phase 2/Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Coumadin
Clinical Trial Phase Trials
Completed 85
Recruiting 13
Terminated 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Coumadin

Sponsor Name

Sponsor Name for Coumadin
Sponsor Trials
M.D. Anderson Cancer Center 14
Bristol-Myers Squibb 9
Genentech, Inc. 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Coumadin
Sponsor Trials
Other 183
Industry 73
NIH 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Boehringer Ingelheim
Mallinckrodt
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.